Amgen and Bairun Announce Strategic Collaboration to Expand Market Access for Prolia® in China

Shanghai, November 11, 2021 /PR Newswire/ --10 Days, Amgen announced that it has reached an agreement with Profex(Shanghai)Co.,Ltd. (referred to as "Profex") regarding Amgen's product——Prolia^®(General Name: Denosumab Injection 60mg) has reached a strategic cooperation for promotion in some commercial channels in China. According to the agreement, Profex(Shanghai)Co.,Ltd. will be responsible for Prolia.^®The promotion in the vast market of China, i.e., the regions outside the core markets currently covered by Amgen China's existing commercialization team.

Strategic Cooperation Signing Ceremony (From left to right: Ailing Xu, Vice President of Amgen and General Manager of Amgen China; Gengmin Xiao, CEO of Profex(Shanghai)Co.,Ltd.)

Prolia^®Approved by the National Medical Products Administration in June 2020 for the treatment of osteoporosis in postmenopausal women at high risk of fractures, it isThe First and Currently Only One in ChinaAnti-RANKL monoclonal antibody drugs for the treatment of osteoporosis help improve patients' bone health management and quality of life. With the aggravation of aging trends in Chinese society, osteoporosis is imposing an increasingly heavy disease burden on China. It is estimated that currently, about 70 million postmenopausal women in China suffer from osteoporosis.¹。

The collaboration between Amgen and Profex(Shanghai)Co.,Ltd., follows the success of Prolia.^®Following its successful inclusion in the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2020)", Amgen has taken another significant step to continuously promote the accessibility of innovative drugs for the benefit of a broader patient population.

Ms. Ada Xu, Vice President of Amgen and General Manager of Amgen China, stated: "To proactively address the challenges of healthy aging, Amgen continues to explore open collaboration models to deepen and accelerate our development in the Chinese market. The strategic cooperation with Profex (Shanghai) Co., Ltd. allows Amgen to focus more on the core market regions we currently cover. Additionally, by leveraging Profex’s market access capabilities in broader markets, our innovative products can reach more Chinese patients in a faster, wider, and more efficient manner, addressing significant unmet medical needs."